Bibliography
- AMIT S, KALGUTKAR, CASTAGNOLI N, JR., TESTA B: Se-lective inhibitor of monoamine oxidase (MAO-A and MAO-13) as probes of its catalytic site and mechanism. Med. Res. Rev. (1995) 15(4):325–388.
- •Comprehensive and fully documented review on the cata-lytic mechanism of selective inhibitors of MAO-A and MAO-B classified by chemical series.
- DOSTERT P: Can our knowledge of monoamine oxi- dase (MAO) help in the design of better MAO inhibi- tors? J. Neural. Transm. (1994) 41 (Suppl.) :269–279.
- •The author places emphasis on possible changes that could be made to improve monoamine oxidase inhibitors.
- WOUTERS J: Structural aspects of monoamine oxidaseand its reversible inhibition. Curr. Med. Chem. (1998) 5:137–162.
- ZHENG-YI, HOTAMISLIGIL C, HVANG GS J-Q etal.: Struc-ture of the human gene for monoamine oxidase Type A. Nucleic Acids Res. (1991) 19:4537–4541.
- HSIU-FEI WU, CHEN K, CHEN SHIH J: Site directed muta-genesis of monoamine oxidase Type A and B: role of cysteines. Mol. Pharmacol (1993) 43:888–893.
- ABELL C-W, STEWART RM, ANDREWS P J, KWAN S-W: Mo-lecular and functional properties of the monoamine oxidases. Heterocycles (1994) 39(2)933–943.
- TIVOL EA, SHALISH C, SCHUBACK DE et al: Mutationalanalysis of the human MAO-A gene. Am. J. Med. Genet. (1996) 67:92–97.
- CHEN K, CHEN SHIH J: Monoamine oxidase Type A and B: structure, function and behaviour. Adv. Pharmacol. (1998) 42:292–296.
- LAUX G, VOLZ H-P, MOLLER H-J: Newer and older monoamine oxidase inhibitors. A comparative pro-file. CNS Drugs (1995) 3(2):145–158.
- GLEITER CH, VOLZ H-P: MAO-A inhibitors - state of theart. Exp. Opin. Invest. Drugs (1996) 5(4):409–419.
- •The article focuses on compounds marketed or under clini-cal investigations and describes the potential clinical indica-tions of reversible MAO-A inhibitors.
- BERLIN I, LECRUBIER Y: Food and drug interactionswith monoamine oxidase inhibitors - How safe are the newer agents? CNS Drugs (1996) 5(6)403–413.
- CURET O, DAMOISEAU G, AUBIN N et al: Befloxatone, anew reversible and selective monoamine oxidase-A in-hibitor. I. Biochemical profile. J. Pharmacol Exp. Ther. (1996) 277:253–264.
- KAGAYA T, KAJIWARA A, NAGATO S et al: E-2011, anovel selective and reversible inhibitor of monoamine oxidase Type A. J. PharmacoL Exp. Ther. (1996), 278(1)243–251.
- KATO M, IWATA H, KATAYAMA T et al: Possible thera-peutic effect of T-794, a novel reversible inhibitor of monoamine oxidase-A, on post-stroke emotional dis-turbances, assessed in animal models of depression. Pharm. Bull. (1997) 20(4):349–353.
- BENTUE-FERRER D, MENARD G, ALLAIN H: Monoamine oxidase B inhibitors - current status and future poten-tial. CNS Drug. (1996) 6(3):217–236.
- •The review focuses on selegiline and compounds under clinical investigations. The potential clinical indications and safety of selective MAO-B inhibitors are discussed.
- ARVANITIS AG, SCHOLFIELD EL, GRIGORIADIS D et al.: Alkylbenzyl ethers of hydroquinones as monoamine oxidase B inhibitors. Biorg. Med. Chem. Lett. (1996) 6(2):115–120.
- ANCHER JF: MD780236. Drugs Future (1984) 9 (8):585–586.
- GATES KS, SILVERMAN RB: 5- (Aminomethy0-3-aryl--2oxazolidinones. A novel class of mechanism-based inactivators of monoamine Oxidase B. J. Am. Chem. Soc. (1990) 112:9364–9372.
- LEBRETON L, CURET O, GUEDDARI S eta].: Selective andpotent monoamine oxidase Type B inhibitors: 2-substituted 5-aryltetrazole derivatives. J. Med. Chem. (1995) 38:4786–4792.
- WOUTERS J, 00MS F, JEGHAM S eta].: Reversible inhibi-tion of Type B monoamine oxidase. Theoretical study of model diazo heterocyclic compounds. Eur. J. Med. Chem. (1997) 32:721–730.
- GLOVER V: Reversible inhibitors of monoamine oxi-dase A (RIMAs) - where can we go from here? In: Antide-pressants: New Pharmacological Strategies. Skolnick P (Ed.), Humana Press, Totowa, New Jersey (1997):69–79.
- ••The author outlines why reversible and mixed inhibitors ofboth MAO-A and MAO-B would be of great interest for se-vere depression.